| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1999;68:1210-1218
© 1999 The Society of Thoracic Surgeons
a Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, South Carolina, USA
Address reprint requests to Dr Zellner, Division of Cardiothoracic Surgery, Medical University of South Carolina, 600 MUSC Complex, Suite 409, Charleston, SC 29425
e-mail: zellnejl{at}musc.edu
Presented at the Forty-fifth Annual Meeting of the Southern Thoracic Surgical Association, Orlando, FL, Nov 12–14, 1998.
Background. All patients undergoing St. Jude Medical valve replacement at the Medical University of South Carolina since January 1979 have been followed prospectively at 12-month intervals.
Methods. This report describes long-term experience in 710 adult patients undergoing isolated aortic (AVR) (418) or mitral valve replacements (MVR) (292) with this prosthesis from January 1979 to December 1996.
Results. Ages ranged from 19 to 84 years (54.8 ± 15.1 AVR, 51.8 ± 12.9 MVR; mean ± SD). Male gender predominated in the AVR group (70%) and female gender in the MVR group (62%). One hundred and fifty-seven patients (22%) had associated coronary artery bypass grafting (AVR 27%, MVR 15%). Thirty-day operative mortality was 5.3% (22/418) in the AVR group and 5.1% (15/292) in the MVR group. Follow-up is 96.9% complete and ranges from 1 month to 16.9 years (AVR, 2,376 patient-years, mean 5.7 ± 4.5 years; MVR, 1,868 patient-years, mean 6.4 ± 4.8 years). In the AVR group, 120 late deaths have occurred and actuarial survival was 78.0 ± 2.3%, 58.0 ± 3.2%, and 36.8 ± 4.8%; at 5, 10, and 15 years, respectively. Forty-six patients have sustained 55 thromboembolic (TE) events (2.3%/patient-year). Fifty-one patients had anticoagulant-related bleeding complications (2.7%/patient-year). The mean improvement in New York Heart Association (NYHA) functional class from preoperative to postoperative was 3.0 ± 0.8 to 1.7 ± 0.1 (p < 0.05). In the MVR group, there have been 84 late deaths, and the actuarial survival was 79.3 ± 2.5%, 60.1 ± 3.5%, and 49.3 ± 4.1% at 5, 10, and 15 years, respectively. Fifty-two patients have had 64 TE events (3.5%/patient-year). Twenty-three patients had anticoagulant-related bleeding complications (1.6%/patient-year). The mean improvement in NYHA functional class was from 3.3 ± 0.6 to 1.8 ± 0.1. There were no mechanical failures in either group.
Conclusions. With a follow-up now extending to 17 years, the St. Jude Medical valve continues to be a reliable mechanical prosthesis with low and stable rates of valve-related complications.
This article has been cited by other articles:
|
|
 |
|
  R. Guenzinger, W. B. Eichinger, I. Hettich, S. Bleiziffer, D. Ruzicka, R. Bauernschmitt, and R. Lange A prospective randomized comparison of the Medtronic Advantage Supra and St Jude Medical Regent mechanical heart valves in the aortic position: is there an additional benefit of supra-annular valve positioning? J. Thorac. Cardiovasc. Surg., August 1, 2008; 136(2): 462 - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Haaverstad, N. Vitale, A. Karevold, G. Cappabianca, A. Tromsdal, P. S. Olsen, L. Kober, H. Ihlen, K. A. Rein, and J. L Svennevig Clinical and echocardiographic assessment of the Medtronic Advantage aortic valve prosthesis: the Scandinavian multicentre, prospective study Heart, April 1, 2007; 93(4): 500 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Baykut, L. Grize, C. Schindler, A. S. Keil, F. Bernet, and H.-R. Zerkowski Eleven-year single-center experience with the ATS Open Pivot Bileaflet heart valve. Ann. Thorac. Surg., September 1, 2006; 82(3): 847 - 852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ikeda, Y. Okazaki, K. Furukawa, S. Ohtsubo, J. Yunoki, M. Natsuaki, and T. Itoh Direct imaging of bileaflet mechanical valve behavior in the tricuspid position. Eur. J. Cardiothorac. Surg., June 1, 2006; 29(6): 1014 - 1019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Guenzinger, W. B. Eichinger, F. Botzenhardt, S. Bleiziffer, I. Wagner, R. Bauernschmitt, S. M. Wildhirt, and R. Lange Rest and Exercise Performance of the Medtronic Advantage Bileaflet Valve in the Aortic Position Ann. Thorac. Surg., October 1, 2005; 80(4): 1319 - 1326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Dagenais, P. Cartier, P. Voisine, D. Desaulniers, J. Perron, R. Baillot, G. Raymond, J. Metras, D. Doyle, and P. Mathieu Which biologic valve should we select for the 45- to 65-year-old age group requiring aortic valve replacement? J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 1041 - 1049. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Tominaga, K. Kurisu, Y. Ochiai, Y. Tomita, M. Masuda, S. Morita, and H. Yasui A 10-Year Experience With the Carbomedics Cardiac Prosthesis Ann. Thorac. Surg., March 1, 2005; 79(3): 784 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J P A Puvimanasinghe, J J M Takkenberg, M B Edwards, M J C Eijkemans, E W Steyerberg, L A van Herwerden, K M Taylor, G L Grunkemeier, J D F Habbema, and A J J C Bogers Comparison of outcomes after aortic valve replacement with a mechanical valve or a bioprosthesis using microsimulation Heart, October 1, 2004; 90(10): 1172 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Vitale, G. Cappabianca, G. Visicchio, C. Fondacone, V. Paradiso, G. Mannatrizio, and L. d. L. T. Schinosa Midterm evaluation of the Sorin Bicarbon heart valve prosthesis: single-center experience Ann. Thorac. Surg., February 1, 2004; 77(2): 527 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Ikonomidis, J. M. Kratz, A. J. Crumbley III, M. R. Stroud, S. M. Bradley, R. M. Sade, and F. A. Crawford Jr Twenty-year experience with the St Jude Medical mechanical valve prosthesis J. Thorac. Cardiovasc. Surg., December 1, 2003; 126(6): 2022 - 2031. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Grunkemeier and Y. Wu "Our complication rates are lower than theirs": Statistical critique of heart valve comparisons J. Thorac. Cardiovasc. Surg., February 1, 2003; 125(2): 290 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.B. Borman and C. De Riberolles Sorin BicarbonTM bileaflet valve: a 10-year experience Eur. J. Cardiothorac. Surg., January 1, 2003; 23(1): 86 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. H. H. Lim, M. Caputo, R. Ascione, J. Wild, R. West, G. D. Angelini, A. J. Bryan, and S. A. M. Calafiore Prospective randomized comparison of CarboMedics and St Jude Medical bileaflet mechanical heart valve prostheses: An interim report J. Thorac. Cardiovasc. Surg., January 1, 2002; 123(1): 21 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.J.M. Takkenberg, J.P.A. Puvimanasinghe, L.A. van Herwerden, E.W. Steyerberg, M.J.C. Eijkemans, J.D.F Habbema, and A.J.J.C. Bogers Prognosis after aortic valve replacement with St. Jude Medical bileaflet prostheses: impact on outcome of varying thromboembolic and bleeding hazards Eur. Heart J. Suppl., December 1, 2001; 3(suppl_Q): Q27 - Q32. [Abstract] [PDF]
|
|
|
|
|
|
D. Pruefer, M. Dahm, G. Dohmen, D. Horstkotte, R. Bergemann, and H. Oelert Intensity of oral anticoagulation after implantation of St. Jude Medical mitral or multiple valve replacement: lessons learned from GELIA (GELIA 5) Eur. Heart J. Suppl., December 1, 2001; 3(suppl_Q): Q39 - Q43. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Zhu and S. S. Feng Fifteen-Year Experience With Shanghai Disc Valve Prosthesis Asian Cardiovasc Thorac Ann, September 1, 2001; 9(3): 182 - 186. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
